Logo image of TNYA

TENAYA THERAPEUTICS INC (TNYA) Stock Price, Quote, News and Overview

NASDAQ:TNYA - Nasdaq - US87990A1060 - Common Stock - Currency: USD

0.4417  -0.01 (-2.67%)

After market: 0.4418 +0 (+0.02%)

TNYA Quote, Performance and Key Statistics

TENAYA THERAPEUTICS INC

NASDAQ:TNYA (5/28/2025, 8:04:15 PM)

After market: 0.4418 +0 (+0.02%)

0.4417

-0.01 (-2.67%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High4.29
52 Week Low0.36
Market Cap71.85M
Shares162.67M
Float161.04M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO07-30 2021-07-30


TNYA short term performance overview.The bars show the price performance of TNYA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60 -80

TNYA long term performance overview.The bars show the price performance of TNYA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of TNYA is 0.4417 USD. In the past month the price decreased by -8.55%. In the past year, price decreased by -89.51%.

TENAYA THERAPEUTICS INC / TNYA Daily stock chart

TNYA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.83 323.41B
AMGN AMGEN INC 13.41 149.70B
GILD GILEAD SCIENCES INC 14.01 134.89B
VRTX VERTEX PHARMACEUTICALS INC N/A 114.30B
REGN REGENERON PHARMACEUTICALS 13.36 63.90B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.23B
ARGX ARGENX SE - ADR 98.17 35.18B
ONC BEIGENE LTD-ADR 6.16 25.99B
BNTX BIONTECH SE-ADR N/A 23.45B
NTRA NATERA INC N/A 22.01B
SMMT SUMMIT THERAPEUTICS INC N/A 19.34B
BIIB BIOGEN INC 8.06 18.69B

About TNYA

Company Profile

TNYA logo image Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. The company is headquartered in South San Francisco, California and currently employs 97 full-time employees. The company went IPO on 2021-07-30. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.

Company Info

TENAYA THERAPEUTICS INC

171 Oyster Point Blvd., Suite 500

South San Francisco CALIFORNIA US

CEO: Faraz Ali

Employees: 140

TNYA Company Website

TNYA Investor Relations

Phone: 14158652066

TENAYA THERAPEUTICS INC / TNYA FAQ

What is the stock price of TENAYA THERAPEUTICS INC today?

The current stock price of TNYA is 0.4417 USD. The price decreased by -2.67% in the last trading session.


What is the ticker symbol for TENAYA THERAPEUTICS INC stock?

The exchange symbol of TENAYA THERAPEUTICS INC is TNYA and it is listed on the Nasdaq exchange.


On which exchange is TNYA stock listed?

TNYA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for TENAYA THERAPEUTICS INC stock?

15 analysts have analysed TNYA and the average price target is 10.35 USD. This implies a price increase of 2242.27% is expected in the next year compared to the current price of 0.4417. Check the TENAYA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is TENAYA THERAPEUTICS INC worth?

TENAYA THERAPEUTICS INC (TNYA) has a market capitalization of 71.85M USD. This makes TNYA a Micro Cap stock.


How many employees does TENAYA THERAPEUTICS INC have?

TENAYA THERAPEUTICS INC (TNYA) currently has 140 employees.


What are the support and resistance levels for TENAYA THERAPEUTICS INC (TNYA) stock?

TENAYA THERAPEUTICS INC (TNYA) has a resistance level at 0.46. Check the full technical report for a detailed analysis of TNYA support and resistance levels.


Should I buy TENAYA THERAPEUTICS INC (TNYA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does TENAYA THERAPEUTICS INC (TNYA) stock pay dividends?

TNYA does not pay a dividend.


What is the Price/Earnings (PE) ratio of TENAYA THERAPEUTICS INC (TNYA)?

TENAYA THERAPEUTICS INC (TNYA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.16).


What is the Short Interest ratio of TENAYA THERAPEUTICS INC (TNYA) stock?

The outstanding short interest for TENAYA THERAPEUTICS INC (TNYA) is 5.42% of its float. Check the ownership tab for more information on the TNYA short interest.


TNYA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

TNYA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to TNYA. The financial health of TNYA is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TNYA Financial Highlights

Over the last trailing twelve months TNYA reported a non-GAAP Earnings per Share(EPS) of -1.16. The EPS increased by 29.27% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -92.65%
ROE -119.68%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%40%
Sales Q2Q%N/A
EPS 1Y (TTM)29.27%
Revenue 1Y (TTM)N/A

TNYA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to TNYA. The Buy consensus is the average rating of analysts ratings from 15 analysts.


Ownership
Inst Owners56.93%
Ins Owners1.51%
Short Float %5.42%
Short Ratio2.24
Analysts
Analysts84
Price Target10.35 (2243.22%)
EPS Next Y40.02%
Revenue Next YearN/A